Ac-225 Targeted Alpha Therapy: Physics & Safety

Actinium-225 (Ac-225) targeted alpha therapy uses the short range and high linear energy transfer of alpha particles to deposit a large, lethal dose inside targeted tumor cells while sparing nearby normal tissue. What makes Ac-225 distinctive is not just that it is an alpha emitter, but that a single Ac-225 decay unleashes a chain of four net alpha emissions and mobile radioactive daughters — a fact that shapes its efficacy, its dosimetry, and its radiation-safety program. ¹²⁸

Interest in Ac-225 has surged because Ac-225-PSMA-617 has produced striking responses in metastatic castration-resistant prostate cancer (mCRPC), including patients who progressed on beta-emitter Lu-177 therapy. ¹³ But the same physics that makes Ac-225 potent also makes it demanding to handle. This guide explains the decay physics, the dosimetry, the clinical evidence, and the practical radiation-safety and regulatory framework that a nuclear medicine program needs before adopting an alpha-therapy service line. DRPS supports these programs through PET/CT and nuclear medicine physics and radioactive material license support.

Introduction

Radiopharmaceutical therapy (RPT) delivers radiation from the inside out by attaching a radionuclide to a molecule that seeks a tumor. Most established RPT agents — including Lu-177 DOTATATE and Lu-177 PSMA — are beta emitters. Beta particles travel millimeters in tissue, producing a useful "crossfire" that can treat cells the targeting molecule does not directly reach, but delivering a relatively low energy density (linear energy transfer, LET) along their path.

Targeted alpha therapy (TAT) takes the opposite approach. Alpha particles travel only a few cell diameters (under about 0.1 mm) but deposit enormous energy over that short path, producing dense clusters of DNA double-strand breaks that cells struggle to repair. ⁷ This high-LET damage can overcome radioresistance and can be effective at far lower administered activities than beta therapy. Ac-225 and its short-lived daughter Bi-213 are the two alpha emitters most developed for conjugatable TAT. ⁶⁷

Ac-225 has become the flagship TAT nuclide for three reasons: a physical half-life of about 9.9 days that is convenient for chemistry and distribution, a decay chain that yields four alpha particles per parent decay for a high energy payload, and demonstrated clinical efficacy when conjugated to PSMA ligands. ⁶⁸ Those same properties — a long half-life, a multi-alpha chain, and recoiling daughters — are exactly what make Ac-225 a careful dosimetry and radiation-protection problem rather than a plug-in replacement for Lu-177.

Topic Explanation

The Ac-225 decay chain

Ac-225 does not decay in a single step. It initiates a chain that proceeds through several short-lived radionuclides to near-stable Bi-209, emitting four alpha particles and two beta particles along the dominant branch. The daughters matter for two reasons: some emit imageable and dose-contributing photons, and their recoil can detach them from the targeting molecule. Representative decay data are drawn from ICRP Publication 107 and national nuclear-data tables. ¹⁰¹¹

Nuclide	Approx. half-life	Principal emission	Note
Ac-225	~9.9 days	α	Parent; sets logistics and dosimetry timescale
Fr-221	~4.9 min	α (with ~218 keV γ)	Daughter photon usable for imaging
At-217	~32 ms	α	Very short-lived
Bi-213	~45.6 min	β⁻ (dominant) / α (~2%); ~440 keV γ	Imageable 440 keV photon
Po-213	~4.2 µs	α	Fourth alpha (dominant branch)
Pb-209	~3.2 h	β⁻	Longer-lived daughter
Bi-209	effectively stable	—	Chain endpoint

The key physics consequence: in secular-like conditions, one Ac-225 decay ultimately produces four alpha decays. The alpha payload is what drives tumor kill, while the Fr-221 (~218 keV) and Bi-213 (~440 keV) photons produce a small external dose and, usefully, allow gamma-camera or SPECT imaging of biodistribution. ⁸¹⁰

High-LET dose and relative biological effectiveness

Alpha particles from this chain carry several MeV and deposit it over a track only micrometers long, giving LET values on the order of ~100 keV/µm — orders of magnitude higher than beta or gamma radiation. Because dense ionization produces clustered, poorly repairable damage, a given absorbed dose of alpha radiation is biologically more effective than the same dose of low-LET radiation. Clinical Ac-225 dosimetry therefore applies a relative biological effectiveness (RBE) weighting; the foundational Ac-225-PSMA-617 dosimetry work used an RBE of 5. ²

Why Ac-225 differs from Lu-177 and Ra-223

All three are used in RPT, but they are not interchangeable:

Lu-177 (beta, ~6.6-day half-life, imageable 113/208 keV photons) is the workhorse beta agent; its radiation-safety profile is dominated by a modest external photon dose. See our Lu-177 theranostics dosimetry guide.
Ra-223 (alpha, delivered as a bone-seeking cation) is dominated by alpha contamination control and body-fluid precautions rather than structural shielding, as covered in Ra-223 dichloride therapy.
Ac-225 is an alpha emitter that can be conjugated to diverse targeting molecules (PSMA, DOTATATE, and others), carries a four-alpha chain, and adds the daughter-recoil problem — daughters that break free and redistribute. ⁶⁸

For the shielding-side comparison of these three nuclides, see our companion piece on RPT shielding for Lu-177, Ra-223, and Ac-225.

Key Technical Principles

Administered activity and decay

Ac-225-PSMA-617 has been dosed empirically by body weight; the widely referenced protocol uses approximately 100 kBq/kg per cycle, repeated every 8 weeks. ² For an 80 kg patient:

A_{0} = 100 kBq/kg \times 80 kg = 8, 000 kBq = 8 MBq

This is a striking contrast to beta therapy: Lu-177 PSMA cycles are typically several GBq, so Ac-225 delivers therapy with roughly a thousandfold lower administered activity because each alpha decay is far more damaging and the chain yields four of them.

The Ac-225 decay constant follows from its half-life:

λ = \frac{ln 2}{T _{1/2}} = \frac{0.693}{9.9 d} \approx 0.070 d^{- 1}

Over an 8-week (56-day) inter-cycle interval, the residual parent activity is:

\frac{A ( 56 )}{A _{0}} = e^{- λ t} = e^{- 0.070 \times 56} \approx e^{- 3.9} \approx 0.02

so only about 2% of the administered Ac-225 remains when the next cycle is given — physical decay, not just biological clearance, has largely removed the parent.

Total alpha payload

The total number of Ac-225 disintegrations from a fully decayed administration equals the initial activity divided by the decay constant (the time-integrated activity if all decay occurred in the body):

N = \frac{A _{0}}{λ} = \frac{8 \times 1 0 ^{6} Bq}{8.1 \times 1 0 ^{- 7} s ^{- 1}} \approx 9.9 \times 1 0^{12} decays

With four net alpha emissions per parent decay, that is on the order of $4 \times 1 0^{13}$ alpha particles — a large high-LET payload delivered from a tiny administered activity. (In practice, biological clearance and daughter redistribution mean not all of this dose is deposited in tumor, which is exactly why dosimetry and daughter behavior matter.)

External dose versus contamination

Because the therapeutic emissions are alphas, the external photon dose is small. Using a representative Ac-225-plus-daughters air-kerma/dose constant on the order of 0.03–0.04 µSv·m²·MBq⁻¹·h⁻¹ from published radiation-protection analyses, an 8 MBq source at 1 m gives an unshielded dose rate of only: ⁸

\dot{D} \approx \frac{0.035 \times 8}{1 ^{2}} \approx 0.28 μ Sv/h

That low external rate is why Ac-225 rarely drives structural shielding. The real hazard is internal contamination: alpha emitters are far more damaging when taken into the body, so ingestion, inhalation, wound contamination, and body-fluid handling dominate the safety program. This is the same lesson learned with Ra-223, amplified by the daughter-recoil issue.

Daughter recoil

When any nuclide in the chain emits an alpha, conservation of momentum imparts a recoil energy to the daughter (tens to ~100+ keV) that vastly exceeds chemical bond energies. The daughter can therefore detach from the targeting molecule and redistribute — Fr-221 and especially the ~45-minute Bi-213 may travel to kidneys or other organs before decaying. ⁶⁸ This "free daughter" dose is a fundamental limitation of Ac-225 dosimetry and a driver of ongoing radiopharmaceutical engineering (fast-internalizing constructs, local retention strategies). For the underlying dose-calculation framework, see our overview of the MIRD schema for internal dosimetry.

Clinical Impact

Ac-225-PSMA therapy has produced some of the most dramatic responses reported in heavily pretreated mCRPC, including patients refractory to Lu-177 PSMA. The first-in-human Ac-225-PSMA-617 reports described complete imaging and biochemical responses in patients who had exhausted standard options. ¹

Pooled evidence from systematic reviews and meta-analyses is consistent:

A meta-analysis of Ac-225-PSMA-617 TAT reported that about 83% of patients showed any PSA decline and about 59% showed a greater-than-50% PSA decline, with a pooled overall-survival proportion of about 81% across included studies. ⁴
A second meta-analysis reported any PSA decline in about 87% and a greater-than-50% decline in about 66%, with a median overall survival near 12.5 months and median progression-free survival near 9 months. ⁵
A prospective real-world cohort reported a median overall survival of about 17 months and median progression-free survival of about 12 months, with disease control even after other options were exhausted. ³

The characteristic dose-limiting toxicity is xerostomia (dry mouth) from PSMA expression in the salivary glands. The foundational dosimetry estimate (RBE 5) found mean doses on the order of ~2.3 Sv/MBq to salivary glands, ~0.7 Sv/MBq to kidneys, and ~0.05 Sv/MBq to red marrow, with the dose composed of roughly 99.4% alpha, 0.5% beta, and 0.1% photon radiation — and severe xerostomia becoming dose-limiting above about 100 kBq/kg per cycle. ² Salivary and renal dose, not marrow, typically constrain Ac-225-PSMA therapy, which is the opposite of the marrow-limited picture common with some beta therapies.

Practical Optimization Tips

Adopting an Ac-225 service is as much an operational and safety project as a clinical one. Practical priorities:

Build the program around contamination control

Treat every step — receipt, assay, compounding if applicable, administration, and waste — as an alpha-contamination problem. Alpha contamination cannot be detected with a standard exposure-rate survey meter; it requires appropriate alpha or alpha/beta contamination monitoring and wipe testing with suitable counting.
Use dedicated, absorbent-lined, clearly demarcated work areas; disposable coverings; and strict glove/PPE discipline. Reinforce the practices in our nuclear medicine decontamination best practices guide.

Plan for the daughters and the long tail

Remember that dose and detectable activity persist through the daughters; Bi-213 (~45 min) and Pb-209 (~3.2 h) keep a sample "hot" after the alpha of interest.
Because the parent half-life is ~9.9 days, contaminated waste and materials must be managed on a weeks-long timescale, and decay-in-storage is far slower than for Tc-99m or F-18.

Verify assay and imaging

Ac-225 dose assay is nontrivial; coordinate with the manufacturer/radiopharmacy on validated assay methods and use the daughter photons (Fr-221 ~218 keV, Bi-213 ~440 keV) for biodistribution imaging where a program pursues post-therapy imaging. ⁸

Manage patient-fluid pathways

Blood, urine, and other body fluids can carry contamination; provide bathroom, hygiene, and caregiver instructions and manage linens and absorbent materials as potentially contaminated.

Common pitfalls to avoid

Assuming "alpha means no radiation-safety issue." The external dose is low, but internal-contamination potential is high.
Copying a Lu-177 SOP. Beta-agent procedures under-address alpha contamination and daughter behavior.
Underestimating waste timescales. The ~9.9-day parent half-life makes storage and disposal a longer commitment than short-lived diagnostics.
Ignoring daughter redistribution in dose estimates. Free daughters can dominate normal-organ dose.

Regulatory Considerations

Ac-225 is byproduct material, so its medical use is governed by NRC 10 CFR Part 35 and the radiation-protection standards of 10 CFR Part 20 — or the equivalent Agreement State program. A compliant program must connect the clinical protocol to license authorization, authorized-user credentialing, written directives, and patient-release evaluation.

Key frameworks:

10 CFR Part 35 — Medical Use of Byproduct Material. Governs authorized users, written directives, dosage determination and administration, and the RSO's responsibilities for therapy radionuclides. A new alpha-therapy agent generally requires appropriate license authorization and confirmation that authorized users meet the training and experience requirements for the relevant category of use. ¹²
10 CFR Part 20 — Standards for Protection Against Radiation. Sets occupational and public dose limits, contamination-control and survey expectations, waste-disposal rules, and the ALARA framework that shapes the whole program. ¹³
NRC NUREG-1556, Volume 9. Program-specific guidance for medical-use licenses, including facility, survey, and radiation-safety expectations relevant to therapy programs. ¹⁴
Patient release. Release of treated patients must be evaluated under the governing patient-release framework; instructions to patients and caregivers should address contamination and dose to others.

Jurisdiction matters. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use of byproduct material under their own radiation-control programs, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and which requirements apply before administering Ac-225. Programs adding alpha therapy should coordinate license amendments, authorized-user documentation, and RSO procedures with experienced radiation safety officer and license support resources.

Frequently Asked Questions (FAQs)

What is Ac-225 targeted alpha therapy?

Actinium-225 (Ac-225) targeted alpha therapy is a radiopharmaceutical treatment that attaches the alpha-emitting radionuclide Ac-225 to a tumor-targeting molecule, such as a PSMA ligand for prostate cancer. The alpha particles deposit very high energy over a range of only a few cell diameters, producing dense, difficult-to-repair DNA damage in targeted cells while largely sparing surrounding tissue.

Why use alpha particles instead of beta particles for therapy?

Alpha particles have a short range in tissue (under about 0.1 mm) and a very high linear energy transfer, so they deliver a large, localized dose that is more lethal per unit dose than beta or gamma radiation and can overcome resistance to conventional therapy. The short range concentrates dose in the targeted cells and limits the crossfire dose to nearby normal tissue.

How is Ac-225 different from Lu-177 and Ra-223?

Lu-177 is a beta emitter with imageable low-energy photons, and Ra-223 is an alpha emitter delivered as a simple cation that concentrates in bone. Ac-225 is an alpha emitter with a four-alpha decay chain that can be conjugated to many targeting molecules, and its recoiling radioactive daughters and daughter photons create distinctive dosimetry and radiation-safety considerations.

What is the daughter recoil problem in Ac-225 therapy?

When Ac-225 and its daughters emit an alpha particle, the recoil energy far exceeds any chemical bond, so daughter radionuclides such as Fr-221 and Bi-213 can break free of the targeting molecule and redistribute in the body. This can deliver dose to non-target organs and is a central challenge in Ac-225 dosimetry and radiopharmaceutical design.

Is Ac-225 mainly an external radiation hazard?

No. Because alpha particles are stopped by a few centimeters of air or the outer layer of skin, the dominant concern is internal contamination from ingestion, inhalation, or wounds, plus body-fluid contamination from treated patients. There is a small external photon dose from daughter emissions, but contamination control usually drives the radiation-safety program.

What regulations govern Ac-225 therapy in the United States?

Ac-225 is byproduct material regulated under NRC 10 CFR Part 35 (medical use) and 10 CFR Part 20 (radiation protection), or the equivalent Agreement State program. Use requires an authorized user, a written directive, appropriate license authorization, patient-specific dosimetry or dosing as applicable, and patient-release evaluation under the governing rules.

Key Takeaways

Ac-225 delivers a four-alpha, high-LET payload from a tiny administered activity (on the order of 100 kBq/kg), making it potent even against therapy-resistant disease. ²⁸
The decay chain and its daughters define the problem — imageable daughter photons help biodistribution imaging, while recoiling free daughters complicate dosimetry. ⁶⁸¹⁰
Clinical results in mCRPC are compelling, with high PSA-response rates and meaningful survival signals, and xerostomia as the characteristic dose-limiting toxicity. ¹³⁴⁵
Contamination control, not shielding, is the safety driver; the external photon dose is low but internal-contamination risk is high.
Waste and storage run on a weeks-long timescale because the parent half-life is ~9.9 days.
Regulation is 10 CFR Parts 35 and 20 (or Agreement State equivalent), requiring authorized users, written directives, license authorization, and patient-release evaluation. ¹²¹³¹⁴

Conclusion

Actinium-225 targeted alpha therapy is one of the most promising developments in radiopharmaceutical oncology, turning the extreme energy density of alpha particles into durable responses in patients who have run out of options. But Ac-225 is not a drop-in alpha version of Lu-177. Its four-alpha decay chain, recoiling daughters, salivary- and renal-limited dosimetry, and internal-contamination hazard demand a program built specifically around alpha physics.

Facilities that treat Ac-225 as its own discipline — with alpha-appropriate contamination monitoring, daughter-aware dosimetry, weeks-long waste planning, and license and authorized-user documentation matched to the agent — will be positioned to offer this therapy safely and defensibly. The physics that makes Ac-225 powerful is the same physics that makes rigor non-optional.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and theranostics programs building or expanding radiopharmaceutical therapy services. For alpha-therapy agents such as Ac-225, this can include radiation-safety program design, alpha-contamination survey and wipe-test strategy, dosimetry framework support, waste and storage planning, radioactive material license support, RSO program guidance, and PET/CT and nuclear medicine physics aligned with NRC and Agreement State requirements.

DRPS serves facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. To discuss an alpha-therapy program, contact our team.

Related Resources

References

Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine. 2016;57(12):1941-1944. doi:10.2967/jnumed.116.178673. doi.org
Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. Journal of Nuclear Medicine. 2017;58(10):1624-1631. doi:10.2967/jnumed.117.191395. doi.org
Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;10(20):9364-9377. doi:10.7150/thno.48107. doi.org
Ballal S, Yadav MP, Sahoo RK, et al. 225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. The Prostate. 2021;81(9):580-591. doi:10.1002/pros.24137. doi.org
Ma J, Li L, Liao T, Gong W, Zhang C. Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Frontiers in Oncology. 2022;12:796657. doi:10.3389/fonc.2022.796657. doi.org
Morgenstern A, Apostolidis C, Bruchertseifer F. Supply and clinical application of actinium-225 and bismuth-213. Seminars in Nuclear Medicine. 2020;50(2):119-123. doi:10.1053/j.semnuclmed.2020.02.003. doi.org
Bruchertseifer F, Kellerbauer A, Malmbeck R, Morgenstern A. Targeted alpha therapy with bismuth-213 and actinium-225: meeting future demand. Journal of Labelled Compounds and Radiopharmaceuticals. 2019;62(11):794-802. doi:10.1002/jlcr.3792. doi.org
Marengo M, Infantino A. Assessment of emission data and transmission factors supporting radiation protection in the use of 225Ac. Physica Medica. 2022;103:59-65. doi:10.1016/j.ejmp.2022.10.007. doi.org
Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Physics. 2012;102(3):271-291. PubMed
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
Laboratoire National Henri Becquerel. Ac-225 decay data tables. lnhb.fr
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov